Genmab Reports 28.2-Month Median Survival in Petosemtamab Combination Trial

07:53 AM EDT, 10/26/2026 (MT Newswires) -- Genmab's (GMAB) petosemtamab, combined with pembrolizumab, demonstrated a median overall survival of 28.2 months in a phase 2 trial in head and neck squamous cell carcinoma, the company said Monday. The trial's updated results also include a 63% overall response rate, a median progression-free survival of nine months in efficacy-evaluable patients, and a 19% complete response rate, Genmab said. Median progression-free survival was nine months among 43 efficacy-evaluable patients, the company said, and median follow-up was 25.5 months as of May 15, 2026. The combination therapy demonstrated a "manageable" safety profile, the company said. The most common side effects were fatigue, acneiform dermatitis and rash, it added. The Phase 3 development program is ongoing, with topline data from the first-line head and neck cancer trial expected later this year, according to the company.